D istinct subsets ofT helper cells, which are delineated on the basis of cytokine-secretion patterns, were initially described in the murine immune system [1] [2] [3] . It has become increasingly clear that such subsets of T cells, termed Th 1 and Th2, can also be identified in humans (4) . Although the first evidence ofTh 1 and Th2 cells in humans came from cell lines or T-cell clones [5 ,6) , recent evidence indicates that these subsets are an important component of the specific T-cell response in several different diseases. Infiltrates of interleukin 4 (IL-4) -and IL-5 -producing cells (Th2 phenotype) that do not produce IL-2 or interferon-y (IFN-Y) have been described in atopic individuals in response to dust-mite allergen [7, 8) . Bronchial lavage fluids from asthma patients have been shown to contain significantly more Th2-like cells than control subjects (9) . Moreover, Yamamura et al have shown using the polymerase chain reaction (PCR) that T cells obtained from lepromatous-type lesions Manuscript received March 1, 1994;  revised June 6, 1994 ; accepted for publication July 12, 1994. Reprint requcsts to: Alain H. Rook , Department of Dermatology , University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104.
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or parapsoriasis had demonstrable IL-4 and/or IL-5 mRNA. Specifically, IL-5 mRNA was detected in skin biopsies from five of six tumor-stage CTCL, two of three plaque-stage CTCL, one of three patch-stage CTCL, and 1 of 3 parapsoriasis patients, whereas IL-4 mRNA was demonstrated to be present in five of six tumor-stage, one of three plaque stage, none of three patch-stage CTCL, and none of three parapsoriasis patients. These results indicate that in all stages of cutaneous involvement of CTCL, encompassing patch stage through tumor stage, IL-4 and IL-5 mRNA is variably detectable. In tumor-stage skin lesions, typically characterized by a dense dermal infiltrate of malignant T cells, Th2 cytokine mRNA is virtually always detectable. The ability to detect Th2 cytokine mRNA in the skin of patients with CTCL supports our previous findings that the malignant T cells in CTCL possess a Th2-helper cell phenotype. Key words: Sezary syndrome/skin neoplasms/mononuclear leukocytes/interleukin.] Invest Dermato1103: [669] [670] [671] [672] [673] 1994 of leprosy patients were positive for IL-4, IL-S, and IL-I0 mRNA, the Th2 phenotype, whereas T cells from tuberculoid-like lesions produced cytokine mRNA consistent with the Th 1 phenotype (IFN-y and IL-2) (10). Parasitic infection, particularly with helminths, has also been shown to evoke a Th2-like cell response (11) .
In addition, activation of T cells via the chemical induction of autoimmunity or graft-v ersus-host disease in rodents appears to most often result in a Th2 cell pattern (reviewed by Goldman et al [12] ). Although the immunologic factors that lead to the generation of a specific T -helper subset response remain to be defined, it appears that Th l-like cells are primarily responsible for mediating delayed-type -hypersensitivity reactions such as that observed in response to certain infections or contact dermati tis, whereas a Th2like response is observed in conditions such as parasitic or allergic reactions characterized by eosinophilia and high-antibody titers, particularly 19B. Patients with Sezary syndrome (SzS), a leukemic form of cutaneous T-cell lymphoma (CTCL) characterized by malignant atypical CD4+jCD45RO+ lymphocytes (Sezary cells) in the skin and peripheral blood, in addition to erythroderma, exhibit an array of immunologic abnormalities that parallel the ill "ilro activities of Th2 cytokines, particularly IL-4 and IL-5 (13) . We have previously shown that peripheral blood monolluclear cells (PBMe) from SzS 0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. patients produce a Th2 cell pattern of cytokine secretion following mitogen-stimulation [14] . Although in that study the source of the Th2 cytokines could not specifically be attributred to the malignant T cell, we observed a direct correlation between the number of Sezary cells and the amount of IL-4 produced, and an inverse correlation between the number of Sezary cells and the production of IL-2 and IFN-y.
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In the present study, we show that these observations can be extended to the detection of Th2 cytokine mRNA in the skin of CTCL patients. Furthermore, we demonstrate that as CTCL progresses from patch to tumor stage, i.e., as the extent of the malignant T-cell infiltrate becomes more marked, the prevalence ofTh2 cytokine mRNA in the skin is more frequent.
MATERIALS AND METHODS
Patients and Skin Samples Patients participating in this study were diagnosed with CTCL based on clinical, histopathologic, and immunohistologic criteria [ Table I ] (reviewed in [15] ). Skin samples, consisting of 4-mm punch biopsies, were obtained from CTCL patients with different stages of cutaneous involvement (patch, plaque, or tumor), or from volunteers with other skin disorders characterized by lymphoid infiltrates including parapsoriasis, lichen planus, and psoriasis. Skin biopsies were also obtained from normal controls. All CTCL patients were sero negative for human T-cell lymphocytic virus-I antibodies by enzyme-linked immunosorbent assay and had no apparent secondary infections or other dermatologic diseases. All skin samples were procured after informed consent was obtained.
Extraction of RNA and Performance of the Polymerase Chain Reaction (peR) Total RNA was extracted from skin biopsies, fresh or snap frozen, using RNAzol B (Tel-Test, Inc. , Friendswood, TX), a modification of the guanidinium thiocyanate isolation method [16] . Following extraction, the RNA was reverse transcribed (RT) as previously described [17] . Briefly, 3 J.!g of total RNA, after brief denaturation at 65"C for 5 min, was incubated at 37"C for 30 min in a cocktail containing RT (BRL/Gibco), deoxynucleotide triphosphates (dNTP, Perkin-Elmer Cetus), oligo (dT), 6 (Sigma), dithiothreitol (BRL), RNase inhibitor (RNAsin, BRL), MgCl 2 , KCI, and Tris buffer in a total volume of20 J.!l. Immediately following RT, 10 J.!I of the RT cocktail was removed for PCR amplification. PCR amplification of cytokine eDNA was accomplished using sense and antisense
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Sezary cell count> 15%, usually much hi gher primers based on previously published sequence data and by selection using a primer selection program, OSP [18] (Table II) . To prevent amplification of any contaminating genomic DNA, all cytokine primers were designed to span introns. To verify the integrity of the RNA and cDNA for each experimental sample, a separate control amplification usi ng p-actin primers was included in the PCR run. The PCR cocktai l consisted ofTris buffer, 2.5 mM MgCI2' 1.5 mM dNTP, 500 ng each of the sense and antisense primers, 1.25 U ofTaq polymerase (Promega), and deionized water in a total volume of 50 J.!l. This PCR cocktail was amplified in a forced -hot-air thermocycler (BioOven II, BioTherm Corp., Fairfax, VA) for 30 cycles where a single cycle consisted of92"C for 1 min, 55°C for 1 min, and 72°C for 1.5 min. To avoid carry-over contamination, strict physical and procedural precautions (separate handlin g areas and dedicated supplies and reagents for pre-and post-amplification) were routinely observed. To monitor for carry-over contamination, a negative control water blank was included in each PCR amplification. Following amplification, a 12-J.!1 sample of the PCR cocktail is sized on a ethidium bromide -containing 3% Nusieve (FMC, Rockland, ME): 1 % agarose (Gibco/B RL) gel run at 90 V for 1 h. The gel was visualized under ultraviolet light and the size of any bands present are compared to molecular weight markers run in a parallel lane. The specific cytokine identity of PCR products was verified by size and by autoradiography using a 32P-a-ATP -labeled nested oligonucleotide probe (Table II) .
RESULTS
Thl Cytokine (IL-2 and IFN-Y) mRNA Expression in Normal Skin To evaluate cytokine expression in CTCL, we initially determined the background expression of cytokine mRNA in normal skin. PCR analysis revealed that skin samples from 12 different normal donors all expressed mRNA for IL-2 and IFN-y; however, IL-4 or IL-5 mRNA was not detected within any of these specimens (Table ill and Fig 1) . It should be stressed that neither IL-2 nor IFN-y mRNA were detected in negative control cDNAfrom HuT 78 cells, a CD4+-transformed T-cell line, or in the negative-control water blanks, indicating that the results obtained in skin samples were not the result of PCR contamination. Thus, normal skin exhibited a Th 1 cytokine pattern.
Th2 Cytokine (IL-4 and IL-S) lI1RNA in Skin Biopsies from CTCL Patients Biopsies of involved skin from CTCL patients were obtained for evaluation of IL-4 and IL-S mRNA expression. Specimens were segre gated into three separate groups based upon clinicopathologic characterization of lesional skin (Table I) and consisted of patch stage (n = 3), plaque stage (n = 3), and tumor stage (n = 6) . In addition, biopsies were taken from patients diagnosed with parapsoriasis (n = 3), a frequent precursor of CTCL [19] . Biopsies from patients with patch-stage disease, the ea rliest stage of CTCL, did not express IL-4 mRNA; however, involved skin from one patient did express IL-S mRNA (Table IV) . In biopsies of plaque-stage disease, one of three specimens expressed IL-4 mRNA, whereas two of three specimens, including the one expressing IL-4 mRNA, had detectable mRNA for IL-S (Table IV) .
In the most advanced stage of CTCL, tumor stage, IL-4 mRNA was detected in all six patients evaluated and IL-S mRNA was present in five of six patients (Table IV ) . The biopsies from parapsoriasis patients demonstrated a similar pattern to that observed within the samples from the patch-stage CTCL patients, with none of three expressing IL-4 mRNA and one of three having detectable IL-S mRNA (Table IV) .
Non-CTCL Lymphoid Infiltrates, Lichen Planus, and Psoriasis Express a Th1 Cytokine Profile Skin samples were also analyzed from volunteers with benign inflammatory dermatoses unrelated to CTCL characterized by the presence of heavy dermal mononuclear cell infi ltrates (psoriasis, n = 2; lichen planus, n = 2). In all four of these specimens, both IFN-y and IL-2 mRNA were detected. However, in contrast to the findings in CTCL, neither IL-4 nor IL-S mRNA was detected in any of the psoriasis or lichen planus biopsies (Table III) .
DISCUSSION
We have previously shown that PBMC from SzS patients produce increased amounts of IL-4 with a concomitant decrease in IL-2 and IFN-y production as compared to normal contro ls [14] . The amoun t TAA TCA CTA CTC ACA TGA ACC T  TGT TGA GAT GAT GCT TTG ACA  CTA TTA CGT TGA TAT TGC T   TCC CCC CTC TGT TCT TCC  GCC TTT CCA CGC CGT TTT CC  CGA GAG GAT CCT GTC GAG CCG TTT   ATG AGG ATG CTT CTG CAT TTG  TCA ACT TTC TAT TAT CCA CTC  TGA AAG ATT TCT TCA GTG CAC AGT AGT TAT ATC TTG GCT TTT CA ACC GAA TAA TTA GTC AGC TT CTT GAT GGT CTC CAC ACT CT ATG GAG AAA ATC TGG CAC TGA TGG AGT TGA AGG TAG AGG GCG ACG TAG CAC AGC TT oflL-4 produced correlated with t he numbers of circulating Sezary cells. Furthermore, we have demonstrated the abi lity of exogenous IFN-y to inhibit the increased IL-4 production by the PBMC from SzS patients [1 4 ]. To extend these data and to investigate further the apparent Th2 cytokine pattern in CTCL, we studied the expression ofThl and Th2 cytokine mRNA in skin lesions from patients with different stages of CTCL. We demonstrate in this study the ability to detect Th2 cytokine mRNA in skin lesions from CTCL patients at all stages of disease encompassing patch stage through tumor stage. However, either IL-4 or IL-S mRNA, or both, were more freque ntl y detected in densely infiltrated lesions characteristic of a more advanced stage of disease. In addition to finding Th2 cytokine mRNA at various stages of disease, mRNA for both IL-2 and IFN-y was expressed in both normal and CTCL involved skin. It is unlikely that the amplification of these two cytokines was the resu lt of contamination of reagents because neither water blanks nor cDNA obtained from normal resting PBMCs or HuT78 cells showed amplification of these cytokines. Because there are no known endogenous skin cell s that produce IL-2 or IFN-y, either constitutively or by induction, these data suggest that skin-trafficking T cells, which are observed in perivascular regions of normal skin [20] , may be primed to produce low levels of IL-2 and IFN-y. Furthermore, perivascular T cells in normal skin often express activation markers such as CD2S and class II HLA antigens [20] . Because IL-2 mRNA production precedes the expression of these activation markers in the normal kinetics of T-cell activation and proliferation [21] , it is not surprising that mRNA for IL-2 or IFN-y is detectable by PCR in normal skin biopsies.
Although RT-PCR ca nnot definitively determine the source of the T h2 cytokines in the involved skin of CTCL, several lines of evidence suggest that IL-4 and IL-S are being produced by the malignant T-cell clone. First, although the numbers of patients is small , there appears to be a correlation between the number and density of malignant T cells that invade the skin with each successive stage of disease and the likelihood that IL-4 and IL-S mRNA w ill be detected. Second , we have previously observed a correlation between the number of circulating malignant T lymphocytes and the amount of IL-4 produced upon activation of PBMCs from SzS patients [14] . Furthermore, PBMC fr0111 SzS patients in remission, as well as PBMC from plaque stage patients without circulating malignant T cells, produced IL-4 in amounts comparable to normal controls [14] . Nevertheless, the recent observation by Dummer and colleagues [22] that mitogen-activated PBMCs from plaque-stage patients lacking Sezary cells did produce variab ly increased amounts ofIL-4 suggests that some reactive lymphoid cells in CTCL may be contributing to Th2 cytokine production.
Although our data suggest that the malignant T-cell clone is the source of T h2 cytokine mRNA, other cutaneous cellular sources cannot be ruled out by our studies. Several recent reports have demonstrated that mas t cells can synthesize and secrete Th2 cytokines [23] ; however, the lack of clinical and histopathologic evidence for mast cell degranulation in these patients suggests that mast cells are not li kely to be the source ofIL-4 or IL-5. Another potential source of lL-5 in these samples are activated eosinophils, which Broide et al have recently shown to be capable of producing IL-5 [24] and are present in increased numbers in Sezary patients. Further investigation into the precise source of the Th2 cytokines is warranted, particularly w ith the use of more specific tec hniques, such as in situ hyb ridi zation, w hich would permit the precise localization of cytokine mRNA.
Al thou gh we are able to detect Th2 cytokine mRNA in clinically involved skin specimens from a large proportion of patients with different histologic stages of CTCL, there are several potential reasons for our fa ilure to detect this pattern in a greater percentage of specimens from earl y CTCL. One plausible explana tion relates to 
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393 kb 220 kb the known interactions between Th 1 and Th2 cytokines, which appear to have reciprocal effects on the opposing T-helper subset, with IFN-y having the capacity to inhibit the expression of Th2 cytokine gene expression [25] . Thus, in early skin lesions of CTCL, a sparse infiltrate of malignant T cell s is prese nt upon a background of normal pre-existing, skin-traffi ckin g Th 1 cells that may play a role in the host immune response to suppress the activity and proliferation of the malignant cells. In support of this, Wood and colleagues have demonstrated tumor-infiltrating CD8+ cytotoxic T cells in early CTCL [26] . Because cytotoxic T cells are a rich source of IFN-y production upon activation [27] , it is likely that the tumor-infiltrating cells may also playa role in the suppression of the Th2 cytokine transcripts below levels that may be routinely detected by our PCR assay. The demonstration of an immunologic milieu characterized by a predominance of Th 1 cytokines in early CTCL reflects the clinical and histologic findings at this stage of disease. IFN-y-mediated suppression of Th2 cell pro liferation may be an important factor responsible for the indol ent course of patch-and plaque-stage disease. Furthermore, the epidermal expression of intercellular adhesion molecule-l (ICAM-l) is known to be an IFN-y-dependent event and is associated with th e significant degree of epidermotropism typical of early disease [28) . As lesions evolve and subsequently demonstrate dermal invas ion characteristic of tumor-stage disease, both ICAM-l expression and the degree of epidermotropism become less profound or completely absent. On the other hand, the aggressive course of advanced disease may result from enhanced tumor-cell proliferation mediated by autocrine stimulation of the numerous malignant cells by increased IL-4 production, which additionally suppresses Th 1 cell responses. Thus, competing Th 1 and Th2 cytokine effects may be important not only in regard to the clinical phenotype and immune defects observed in CTCL [13) , but disordered cytokine regu lation may also be an essential factor in the events critical to progression of disease .
The presence of a cytokine imbalance that contributes to the progression of CTCL has important therapeutic implications. One obvious strate gy might involve rep lace ment of deficient Thl cytokines via the administration of currently ava ilable recombinant proteins. Limited trials of the use of IFN-y for CTCL have demonstrated some clinical benefit of this cytokine [29) . More importantly, IFN -a, which also mediates Th 1 responses by a variety of mechanisms [30), has extremely potent biologic activity in the treatment of CTCL [31] . We have noted the normalization of the cytokine profile in concert with the normalization of certain critical immune functions while experiencing a complete clinical remission during therapy with IFN-a among patients with Sezary syndrome and elevated IL-4 production [Vowels BR, Lessin SR, Cassin M, Benoit BM, Rook AH: Normalization of cytokine secretion patterns and immune function following disappearance of malignant clone from the peripheral blood of a Sezary syndrome (SzS) patient (abstr).] Invest Dermato/100:556, 1993]. Thus, as additional critical immune factors are identified that favor the evolution of Th 1 responses, such as IL-12, which is a potent inducer ofThl responses ( [32] , and Rook AH, Kubin M, Vonderheid EC, Cassin M, Vowels BR, Wolfe JT, Wolf S, Trinchieri G, Lessin SR: Interleukin-12 (IL-12) reverses cytokine and immune abnormalities ofSezary syndrome (abstr). ] IlIlIest Dermato/102 :557, 1994), their therapeutic application in CTCL may prove beneficial.
